B. Riley Weighs in on Agenus’ FY2024 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Stock analysts at B. Riley cut their FY2024 earnings per share estimates for Agenus in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will earn ($10.51) per share for the year, down from their previous estimate of ($6.27). B. Riley has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Agenus’ current full-year earnings is ($6.27) per share. B. Riley also issued estimates for Agenus’ Q4 2024 earnings at ($1.56) EPS, Q1 2025 earnings at ($2.13) EPS, Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($2.07) EPS, FY2025 earnings at ($5.83) EPS, FY2026 earnings at ($8.68) EPS, FY2027 earnings at ($7.86) EPS and FY2028 earnings at ($2.20) EPS.

Several other research analysts have also recently weighed in on AGEN. HC Wainwright cut their price objective on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 12th. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.

Agenus Trading Up 3.9 %

Shares of Agenus stock opened at $2.67 on Wednesday. The stock has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $8.46. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The company has a market capitalization of $62.64 million, a P/E ratio of -0.24 and a beta of 1.39.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently added to or reduced their stakes in AGEN. Point72 DIFC Ltd bought a new position in shares of Agenus during the 2nd quarter valued at about $51,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Agenus during the 2nd quarter valued at about $106,000. EP Wealth Advisors LLC bought a new position in shares of Agenus during the 3rd quarter valued at about $55,000. HighTower Advisors LLC increased its position in shares of Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 7,530 shares during the last quarter. Finally, Blair William & Co. IL bought a new position in shares of Agenus during the 2nd quarter valued at about $441,000. 61.46% of the stock is currently owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.